Skip to main content
Premium Trial:

Request an Annual Quote

ACT Genomics Acquires MC Diagnostics

NEW YORK – Asian molecular diagnostic firm ACT Genomics announced on Tuesday that it has completed its acquisition of MC Diagnostics.

Financial terms of the deal were undisclosed.

The companies plan to develop fusion gene chips on MC Diagnostics' automated low density array platform, known as ALDAS, that can be performed at the point of care, ACT said in a statement. The first gene chip, called the ACTSpot NTRK, will be launched in August.

United Kingdom-based MC Diagnostics offers automated multiplex molecular tests and image analysis and interpretation software. The firm also offers HLA typing and blood group diagnostics on its ALDAS platform.

The ALDAS system has an eight-well strip array that allows up to 96 samples to be run at a time, with a turnaround time of three hours, ACT said.

Taipei-based ACT Genomics specializes in next-generation sequencing-based tests and oncology molecular diagnostics. The firm provides cancer treatment planning, immunotherapy evaluation, cancer relapse and drug resistance monitoring, and cancer risk assessment.